| 1344 |
National Cancer Institute |
Html |
en |
How To Handle Withdrawal Symptoms and Triggers When You Decide To Quit Smoking |
This fact sheet provides helpful tips related to smoking cessation. |
| routine smoke breaks | 0.282965 |
| smoking effects | 0.278771 |
| relaxation techniques | 0.313407 |
| nicotine addiction | 0.355656 |
| Control Research Branch | 0.30123 |
| Yes. Nicotine replacement | 0.344131 |
| nicotine withdrawal symptoms | 0.36823 |
| urge | 0.354906 |
| tips | 0.337093 |
| negative feelings | 0.295635 |
| Nicotine nasal spray | 0.380205 |
| tea | 0.279209 |
| Tobacco Control Research | 0.298555 |
| things | 0.265705 |
| tobacco smoke | 0.262113 |
| nicotine replacement therapy | 0.347084 |
| drinking coffee | 0.292775 |
| highly dependent smokers | 0.261935 |
| daily life | 0.289451 |
| Smoking Quitline | 0.271985 |
| Step-by-Step Quit Guide | 0.333256 |
| nicotine replacement products | 0.922705 |
| help quitting tobacco | 0.287795 |
| nicotine replacement product | 0.346885 |
| smoking increase | 0.274802 |
|
| weight gain | 0.385772 |
| smokers | 0.365077 |
| counter weight gain | 0.289631 |
| nicotine cravings | 0.53551 |
| nicotine doses | 0.315612 |
| common negative feelings | 0.293918 |
| smoking | 0.59993 |
| nicotine lozenge | 0.318321 |
| nicotine inhaler | 0.328106 |
| nicotine travels | 0.313333 |
| nicotine level drops | 0.347286 |
| chews nicotine gum | 0.341989 |
| people | 0.407906 |
| strong urge | 0.298124 |
| physical activity | 0.320031 |
| people smoking | 0.295038 |
| nicotine gum | 0.386182 |
| nicotine patch | 0.339006 |
| withdrawal symptoms | 0.655994 |
| common withdrawal symptoms | 0.360181 |
| coffee | 0.312007 |
| smoking cessation trials | 0.292819 |
| Occasional mild cravings | 0.284899 |
| time | 0.303672 |
|
CLICK HERE |
| 1447 |
National Cancer Institute |
Html |
null |
Unusual Cancers of Childhood Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of unusual cancers of childhood such as cancers of the head and neck, chest, abdomen, reproductive system, skin, and others. |
|
|
CLICK HERE |
| 1495 |
National Cancer Institute |
Html |
en |
Hairy Cell Leukemia Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of hairy cell leukemia. |
| purine analog therapy | 0.544174 |
| BRAF inhibitor | 0.537215 |
| overall response rate | 0.600065 |
| cell leukemia patients | 0.629349 |
| purine analogs | 0.574118 |
| Hot Flashes | 0.53761 |
| complete remission rate | 0.547966 |
| long-term follow-up | 0.53699 |
| long term follow-up | 0.54098 |
| Tiacci et al. | 0.545702 |
| Foucar MK | 0.540256 |
| classic-form hairy cell | 0.592078 |
| cell leukemia variants. | 0.563299 |
| peripheral blood counts | 0.541349 |
| Pettirossi et al. | 0.546064 |
| median overall survival | 0.57455 |
| 9-year median follow-ups | 0.545986 |
| patients | 0.634056 |
| continuous infusion | 0.540582 |
| multicenter studies | 0.537514 |
| VH4-34+ hairy cell | 0.567746 |
| B-cell lymphomas | 0.539052 |
| Rosenberg et al. | 0.545728 |
| Natl Cancer Inst | 0.537773 |
|
| hairy-cell leukemia | 0.564359 |
| Night Sweats | 0.538245 |
| et al. | 0.547621 |
| median treatment-free survival | 0.574134 |
| partial remission rate | 0.543701 |
| stable partial remission | 0.545722 |
| cladribine | 0.537399 |
| complete remissions | 0.537086 |
| one-time continuous infusion | 0.53916 |
| comparable response rates | 0.548208 |
| treatment option | 0.539331 |
| median follow-up | 0.54766 |
| potential increased risk | 0.575127 |
| cell leukemia variant | 0.57205 |
| overall response rate. | 0.539597 |
| complete response rate | 0.636139 |
| Abstract | 0.548918 |
| hairy cell leukemia | 0.918712 |
| Clin Oncol | 0.592807 |
| subcutaneous injections | 0.544059 |
| PDQ summary | 0.53807 |
| cell leukemia variants | 0.563543 |
| previously untreated patients | 0.548389 |
| standardized incidence ratio | 0.536889 |
|
CLICK HERE |
| 1611 |
National Cancer Institute |
Html |
en |
Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version |
Serious, disabling, and life-threatening chronic health conditions adversely affect the health of aging childhood cancer survivors. Learn about the cardiovascular, cognitive, psychosocial, digestive, endocrine, immune, musculoskeletal, reproductive, and urinary late effects and subsequent neoplasms that contribute to a high burden of morbidity in childhood cancer survivors. |
| adult cancer survivors | 0.344142 |
| childhood leukemia survivors | 0.307057 |
| Childhood Cancer Guideline | 0.302298 |
| childhood cancer therapy | 0.296791 |
| long-term cancer survivors | 0.295333 |
| childhood cancer survivors | 0.499567 |
| Engl J Med | 0.269755 |
| Br J Cancer | 0.261959 |
| Cancer Survivor cohort | 0.269169 |
| Int J Cancer | 0.266011 |
| Ann Intern Med | 0.263377 |
| 5-year survivors | 0.295172 |
| cancer survivors research | 0.286942 |
| Radiat Oncol Biol | 0.277048 |
| breast cancer surveillance | 0.269328 |
| adult survivors | 0.315122 |
| Hudson MM | 0.309712 |
| young adult cancer | 0.340977 |
| British Childhood Cancer | 0.326521 |
| Natl Cancer Inst | 0.402086 |
| survivor study cohort | 0.273371 |
| Clin Cancer Res | 0.263669 |
| Irradiated Childhood Cancer | 0.298512 |
| childhood cancer | 0.912384 |
| cancer survivor study | 0.693286 |
|
| et al. | 0.431618 |
| late effects | 0.3275 |
| long-term survivors | 0.333244 |
| cohort study | 0.263432 |
| Cancer Epidemiol Biomarkers | 0.265429 |
| pediatric cancer survivors | 0.286679 |
| PUBMED Abstract | 0.35078 |
| Pediatr Blood Cancer | 0.447984 |
| radiation-induced breast cancer | 0.26406 |
| breast cancer risk | 0.280733 |
| Abstract | 0.467444 |
| Clin Oncol | 0.515912 |
| breast cancer | 0.391476 |
| Oncol Biol Phys | 0.278259 |
| childhood cancer survivor | 0.771953 |
| Cancer Guideline Harmonization | 0.260525 |
| young cancer survivors | 0.275759 |
| childhood cancer registry | 0.291062 |
| long-term follow-up guidelines | 0.273165 |
| Cancer J Clin | 0.270171 |
| report | 0.265432 |
| childhood cancer treatment | 0.287484 |
| oncology group | 0.32484 |
| long-term childhood cancer | 0.311378 |
|
CLICK HERE |
| 2029 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de mama y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| Sestak I | 0.314213 |
| Methods Mol Biol | 0.309681 |
| menor incidencia | 0.315649 |
| Breast Cancer Surveillance | 0.32247 |
| largo plazo | 0.325123 |
| Risk Calculator | 0.330192 |
| Cuzick J | 0.314017 |
| breast cancer prevention | 0.340448 |
| útero intacto | 0.328063 |
| Estados Unidos | 0.337849 |
| menor riesgo | 0.381674 |
| cancer prevention trial | 0.330827 |
| Women's Health Initiative | 0.311811 |
| principal factor | 0.31767 |
| Health Initiative | 0.316067 |
| from benign breast | 0.320129 |
| Breast density | 0.313434 |
| lobular breast | 0.315708 |
| English record linkage | 0.310983 |
| hormonas estrógeno | 0.31642 |
| health study | 0.316005 |
| benign breast | 0.353338 |
| Cancer Res Treat | 0.315355 |
| Cancer Risk Assessment | 0.316082 |
| Epidemiol Biomarkers Prev | 0.309854 |
|
| enfermedad proliferativa benigna | 0.311069 |
| Goss PE | 0.314786 |
| antecedentes familiares | 0.49279 |
| Breast Risk Calculator | 0.318395 |
| prospective cohort study | 0.311422 |
| breast cancer risk | 0.370651 |
| reducción promedio | 0.315263 |
| breast cancer | 0.951386 |
| cardiopatÃa coronaria | 0.328283 |
| riesgos instantáneos | 0.314306 |
| IBIS-I breast | 0.313331 |
| risk factor | 0.343815 |
| mujeres portadoras | 0.329041 |
| Cancer Surveillance System | 0.312955 |
| IBIS Breast Cancer | 0.320333 |
| heritable risk factor | 0.311842 |
| Risk Calculator Tool | 0.311 |
| Reino Unido | 0.311996 |
| Women’s Health Initiative | 0.309787 |
| Breast Cancer Referral | 0.321555 |
| parenchymal patterns as | 0.309616 |
| Otro estudio | 0.316688 |
| Breast Cancer Res | 0.357313 |
| mujeres jóvenes | 0.346647 |
|
CLICK HERE |
| 2052 |
National Cancer Institute |
Html |
es |
Terapias biológicas para el cáncer |
Hoja informativa sobre la función del sistema inmunitario; describe la acción de las terapias biológicas. |
| Haluska FG | 0.420038 |
| Redig AJ | 0.419038 |
| ARN mensajero | 0.423865 |
| killer cell-based immunotherapy | 0.432963 |
| células hijas | 0.643617 |
| Canese P | 0.41842 |
| O'Day SJ | 0.419485 |
| clinical applications | 0.420154 |
| we tilt | 0.419245 |
| immune system | 0.418755 |
| altas dosis | 0.418691 |
| linfocitos b | 0.794775 |
| antÃgeno cd52 | 0.453352 |
| Translational Medicine | 0.419593 |
| Comité Asesor | 0.418458 |
| biological therapy | 0.455134 |
| Internal Medicine | 0.419677 |
| Estados Unidos | 0.448833 |
| Expert Opinion | 0.421046 |
| linfocitos t | 0.82421 |
| intrusos foráneos | 0.428976 |
| towards immune-mediated | 0.419994 |
| PubMed Abstract | 0.779921 |
| metastatic melanoma | 0.424461 |
| madre sanas formadoras | 0.440701 |
|
| terapia modificadora | 0.491313 |
| Abeloff's Clinical Oncology | 0.43296 |
| mARN blanco | 0.422446 |
| antÃgeno cd20 | 0.515911 |
| bacteria bacilo | 0.445994 |
| Improved survival with | 0.436486 |
| invasores foráneos | 0.480692 |
| células madre | 0.955075 |
| molécula her-2 | 0.428705 |
| Cancer immunology | 0.420503 |
| Ningún virus | 0.447968 |
| on tumor immunology | 0.437409 |
| McDermott DF | 0.418981 |
| envoltorio protector | 0.421713 |
| IFN)-dependent activation | 0.420375 |
| terapia biológica usa | 0.634008 |
| 90Y‑ibritumomab tiuxetán | 0.424391 |
| ingenierÃa genética | 0.421138 |
| sistema inmunitario. aún | 0.450887 |
| escasa toxicidad | 0.422699 |
| biológica usa organismos | 0.547748 |
| Aún más | 0.468819 |
| virus vector | 0.444624 |
| New England Journal | 0.430623 |
|
CLICK HERE |
| 2069 |
National Cancer Institute |
Html |
es |
Enfermedad de Paget de seno |
Hoja informativa sobre la enfermedad de Paget de seno, un tipo poco común de cáncer que algunas veces se llama enfermedad de Paget del pezón o enfermedad de Paget de mama. |
| Lippincott Williams | 0.227873 |
| Tumor Characteristics | 0.23784 |
| Eisner MP | 0.227823 |
| cáncer invasor | 0.852818 |
| afecciones benignas | 0.232299 |
| Cody HS | 0.226638 |
| Female Breast | 0.245015 |
| posibles tumores | 0.243494 |
| long-term follow-up study | 0.244429 |
| Breast Cancer Research | 0.268606 |
| siglo xix sir | 0.249073 |
| breast-conserving therapy | 0.228801 |
| Lippman ME | 0.226791 |
| ganglios linfáticos centinela | 0.294176 |
| afección benigna | 0.309089 |
| SEER Program | 0.276615 |
| Kanitakis J | 0.22651 |
| estadio i | 0.22947 |
| Hasson D | 0.226314 |
| European Institute | 0.226377 |
| Keel GE | 0.226988 |
| PubMed Abstract | 0.996634 |
| Haffty BG | 0.225876 |
| clinical presentation | 0.228015 |
| Therapeutic options | 0.226841 |
|
| with radiotherapy | 0.228051 |
| Tucker SL | 0.226414 |
| Paget mamaria | 0.499743 |
| estadio iv | 0.228625 |
| End Results | 0.22623 |
| Griffith KA | 0.226914 |
| signo revelador | 0.231703 |
| proteÃna her2 | 0.228884 |
| National Cancer Institute | 0.247867 |
| 4th ed | 0.228822 |
| Sosnovskikh I | 0.226721 |
| Ries LAG | 0.280943 |
| edad promedio | 0.227469 |
| Breast Journal | 0.241614 |
| Osborne CK | 0.226941 |
| Sir James Paget | 0.694935 |
| Cancer Survival Among | 0.251885 |
| estadio iii | 0.228362 |
| Gatti G | 0.22751 |
| Retrieved April | 0.227819 |
| sentinel lymph | 0.278815 |
| European Academy | 0.22756 |
| extramammary paget | 0.443981 |
| Dimaio DJ | 0.226799 |
|
CLICK HERE |
| 2972 |
National Cancer Institute |
Video |
en |
Reach out and offer her a helping hand: A Smokefree Pregnancy Video |
We know quitting smoking is tough, and becoming pregnant doesn't suddenly make it easier. "Reach Out & Offer Her a Helping Hand" is intended to rally the American public's support for all mamas-to-be trying to put out the cigs. For more info on how you can help that special lady in your life quit smoking for good, visit: women.smokefree.gov |
| SmokefreeWomen | 0.826013 |
| Healthier Summer Sweets | 0.545266 |
| 04 | 0.327172 |
| women.smokefree.gov | 0.329 |
| NCI Smokefree | 0.680659 |
| Good Night | 0.430291 |
| Positive Environment | 0.433577 |
| life | 0.329079 |
| NCI Smokefree Pregnancy | 0.635056 |
| Challenge | 0.408491 |
| Motivator | 0.335402 |
| American public | 0.460348 |
| smoking | 0.356739 |
| smoke smell | 0.447387 |
| Smokefree Voices Video | 0.623419 |
| Contest | 0.32649 |
| How-to Video | 0.421251 |
| Blog | 0.32681 |
| views | 0.825633 |
| busy schedule | 0.430343 |
|
| info | 0.329188 |
| Helping Hand | 0.601743 |
| Reach | 0.325318 |
| Smokefree Women | 0.817171 |
| Voiceover | 0.330521 |
| Duration | 0.991806 |
| autoplay | 0.374808 |
| NCI Smokefree Women | 0.669737 |
| De-stress | 0.333641 |
| special lady | 0.458682 |
| Offer | 0.359013 |
| Street Team Video | 0.555716 |
| Clean house | 0.432823 |
| newest video | 0.459372 |
| Fitting fitness | 0.42414 |
| visit | 0.325778 |
| cigs | 0.329305 |
| support | 0.329395 |
| Healthy Body Image | 0.533317 |
|
CLICK HERE |
| 14601 |
National Cancer Institute |
Html |
en |
Childhood Vascular Tumors Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood vascular tumors. |
| lesions | 0.459907 |
| body | 0.444762 |
| PDQ cancer information | 0.428885 |
| steroid therapy | 0.431929 |
| malignant tumors | 0.409372 |
| clinical trials | 0.622735 |
| aggressive vascular tumors | 0.43708 |
| congenital hemangioma | 0.425723 |
| cancer information summary | 0.40263 |
| Diagnostic Tests | 0.677407 |
| liver | 0.469914 |
| lobular capillary hemangioma | 0.410892 |
| blood vessels | 0.494734 |
| pyogenic granuloma | 0.401485 |
| diffuse tumors | 0.399482 |
| benign vascular tumor | 0.531292 |
| vascular tumors | 0.851122 |
| clinical trial | 0.485314 |
| spindle cell hemangiomas | 0.4591 |
| malignant vascular tumors | 0.461238 |
| radiation therapy | 0.585507 |
| following | 0.416254 |
| late effects | 0.40785 |
| General Information section | 0.953371 |
|
| treatment | 0.883924 |
| blood vessel | 0.40513 |
| childhood vascular tumor | 0.423751 |
| skin | 0.519128 |
| vascular tumor | 0.671886 |
| benign vascular tumors | 0.586046 |
| infantile hemangiomas | 0.495631 |
| signs | 0.415044 |
| treatment clinical trials | 0.412572 |
| procedures | 0.39986 |
| multiple lesions | 0.412762 |
| tumor cells | 0.435841 |
| new treatment | 0.424941 |
| topical beta-blocker therapy | 0.421578 |
| kaposiform hemangioendothelioma | 0.442163 |
| hemangiomas | 0.524006 |
| risk factor | 0.415027 |
| childhood vascular tumors | 0.50237 |
| benign tumors | 0.412061 |
| blood vessel tumors | 0.39943 |
| kaposi sarcoma | 0.437901 |
| standard treatment | 0.431582 |
| diffuse liver tumors | 0.410968 |
| surgery | 0.449251 |
|
CLICK HERE |
| 16840 |
National Cancer Institute |
Html |
en |
Companies Formed by PIs of the NCI Alliance for Nanotechnology in Cancer |
The NCI Alliance for Nanotechnology in Cancer has continued to translate solutions from the bench to products. Find out the companies that have been formed by Alliance funded research. |
| clinical products | 0.627038 |
| Alliance members | 0.614849 |
| academic laboratories | 0.654334 |
| for-profit partners | 0.714957 |
| start-ups | 0.300298 |
| clinical communities | 0.60175 |
| venture capital funds | 0.950483 |
| investigators | 0.301645 |
| partnerships | 0.289977 |
| start-up companies | 0.650807 |
| patents | 0.29414 |
| large pharmaceutical companies | 0.926075 |
|
| translational research | 0.68727 |
| significant investment | 0.618191 |
| Alliance PIs | 0.780886 |
| efficient development | 0.679103 |
| IP | 0.327964 |
| Alliance model | 0.651092 |
| services | 0.276826 |
| start-up companies. | 0.723832 |
| technologies | 0.28746 |
| biotechnology firms | 0.63767 |
| form | 0.28731 |
| discoveries | 0.300415 |
|
CLICK HERE |